TABLE 3.
Recognition of autologous tumor cellsa
| Histology | Target cell lines | HPV type | Effector TIL % spe- cific lysis | Shared MHC alleles |
|---|---|---|---|---|
| Hematopoietic | Daudi | 0 | ||
| K562 | 0 | |||
| Melanoma | Mel 397 | 15 | A1 | |
| Mel 642 | 2 | |||
| Renal cell cancer | RCC1940 | 0 | A1 | |
| RCC1897 | 0 | A1, C1 | ||
| Colorectal cancer | SW480 | 0 | B7 | |
| HT29 | 0 | A1 | ||
| Cervical cancer | HT3 | 0 | Nil | |
| C33-A | 0 | B7 | ||
| Caski | 16 | 0 | B7, DR8, 15, DQ4, 6 | |
| Siha | 16 | 0 | DR15, DQ6 | |
| C41 | 18 | 0 | A1, DR8, DQ4 | |
| MS751 | 18 | 0 | ||
| Me180 | 68 | 0 | A1, C7 | |
| CC-H1 | 16 | 40 | All alleles (autol- ogous tumor) | |
| CC-H1+ anti- class I MAb | 16 | 38 | ||
| CC-H1+ anti- class II MAb | 16 | 15 | ||
| Fibroblasts | CC-H1− fibroblasts | 0 |
Tumor cell lines of different histology were used to evaluate MHC class II-restricted recognition of the CD4+ TIL line from patient MZ-CC01-3 in a standard 51Cr-release assay. Note that TIL recognize exclusively autologous tumor cells, which could be blocked using an anti-MHC class II (DR)-specific MAb (clone 243). TIL do not recognize the cervical cancer cell line Caski, which has both HLA-DR and HLA-DQ alleles and also harbors HPV-16. All target cell lines could potentially be lysed, since they represent targets for 7-day LAK cells cultured in 1,000 IU of IL-2/ml. TIL lines from patients MZ-CC01-1 or MZ-CC01-2 did not lyse autologous tumor cells (data not shown). We noted no difference between lysis and cytokine (IFN-γ) production regarding the response to the targets listed in the table (data not shown).